Classic Serotonergic Psychedelics for Mood and Depressive Symptoms: a Meta-analysis of Mood Disorder Patients and Healthy Participants

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2021 Jan 11

PMID 33427944

Citations 43

Authors

Nicole L Galvao-Coelho

Wolfgang Marx

Maria Gonzalez

Justin Sinclair

Michael De Manincor

Daniel Perkins

Jerome Sarris

Affiliations

Soon will be listed here.

Abstract

Rationale: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option.

Objective: We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy and clinical populations (separately).

Results: Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium (2-7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms.

Conclusion: Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms.

Citing Articles

A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.

Wen A, Singhal N, Jones B, Zeifman R, Mehta S, Shenasa M Psychedelic Med (New Rochelle). 2025; 2(1):15-24.

PMID: 40051762 PMC: 11658677. DOI: 10.1089/psymed.2023.0028.

Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics.

Tiwari P, Berghella A, Sayali C, Doss M, Barrett F, Yaden D Psychedelic Med (New Rochelle). 2025; 1(2):74-86.

PMID: 40046726 PMC: 11658661. DOI: 10.1089/psymed.2023.0010.

Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons.

Petruskova A, Guhathakurta D, Akdas E, Perello-Amoros B, Frischknecht R, Weiss E J Neurochem. 2025; 169(3):e70020.

PMID: 40022486 PMC: 11871419. DOI: 10.1111/jnc.70020.

Can psychedelic use benefit meditation practice? Examining individual, psychedelic, and meditation-related factors.

Jiwani Z, Goldberg S, Stroud J, Young J, Curtin J, Dunne J PLoS One. 2025; 20(2):e0310160.

PMID: 39937729 PMC: 11819602. DOI: 10.1371/journal.pone.0310160.

Understanding Suicidal Thoughts and Behaviors Among LGBTQ + Youth: Differential Associations Between Bullying and Substance Use.

Tiedge C, Valido A, Rivas-Koehl M, Garcia B, Robinson L, Clements G Prev Sci. 2025; .

PMID: 39934543 DOI: 10.1007/s11121-025-01783-1.

References

Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B . Treatment resistant depression: A multi-scale, systems biology approach. Neurosci Biobehav Rev. 2017; 84:272-288. PMC: 5729118. DOI: 10.1016/j.neubiorev.2017.08.019. View

Araujo A, Carvalho F, Bastos M, Guedes de Pinho P, Carvalho M . The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 2015; 89(8):1151-73. DOI: 10.1007/s00204-015-1513-x. View

Baumeister D, Barnes G, Giaroli G, Tracy D . Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol. 2014; 4(4):156-69. PMC: 4104707. DOI: 10.1177/2045125314527985. View

BERLIN L, Guthrie T, WEIDER A, GOODELL H, Wolff H . Studies in human cerebral function: the effects of mescaline and lysergic acid on cerebral processes pertinent to creative activity. J Nerv Ment Dis. 1955; 122(5):487-91. View

Bershad A, Schepers S, Bremmer M, Lee R, de Wit H . Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019; 86(10):792-800. PMC: 6814527. DOI: 10.1016/j.biopsych.2019.05.019. View

Blier P, De Montigny C . Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994; 15(7):220-6. DOI: 10.1016/0165-6147(94)90315-8. View

Blum K, Futterman S, Pascarosa P . Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale. Clin Toxicol. 1977; 11(4):459-72. DOI: 10.3109/15563657708988210. View

Bogenschutz M, Ross S . Therapeutic Applications of Classic Hallucinogens. Curr Top Behav Neurosci. 2017; 36:361-391. DOI: 10.1007/7854_2016_464. View

Bogenschutz M, Forcehimes A, Pommy J, Wilcox C, Barbosa P, Strassman R . Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015; 29(3):289-99. DOI: 10.1177/0269881114565144. View

10.

Carhart-Harris R, Williams T, Sessa B, Tyacke R, Rich A, Feilding A . The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. J Psychopharmacol. 2010; 25(11):1562-7. DOI: 10.1177/0269881110367445. View

11.

Carhart-Harris R, Bolstridge M, Rucker J, Day C, Erritzoe D, Kaelen M . Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016; 3(7):619-27. DOI: 10.1016/S2215-0366(16)30065-7. View

12.

Carhart-Harris R, Kaelen M, Bolstridge M, Williams T, Williams L, Underwood R . The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016; 46(7):1379-90. DOI: 10.1017/S0033291715002901. View

13.

Carhart-Harris R, Roseman L, Bolstridge M, Demetriou L, Nienke Pannekoek J, Wall M . Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017; 7(1):13187. PMC: 5640601. DOI: 10.1038/s41598-017-13282-7. View

14.

Carhart-Harris R, Bolstridge M, Day C, Rucker J, Watts R, Erritzoe D . Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2017; 235(2):399-408. PMC: 5813086. DOI: 10.1007/s00213-017-4771-x. View

15.

Carvalho A, Sharma M, Brunoni A, Vieta E, Fava G . The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom. 2016; 85(5):270-88. DOI: 10.1159/000447034. View

16.

Chi T, Gold J . A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020; 411:116715. DOI: 10.1016/j.jns.2020.116715. View

17.

Cipriani A, Furukawa T, Salanti G, Chaimani A, Atkinson L, Ogawa Y . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128):1357-1366. PMC: 5889788. DOI: 10.1016/S0140-6736(17)32802-7. View

18.

Conway C, George M, Sackeim H . Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression: When Enough Is Enough. JAMA Psychiatry. 2016; 74(1):9-10. DOI: 10.1001/jamapsychiatry.2016.2586. View

19.

Corriger A, Pickering G . Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019; 13:3051-3067. PMC: 6717708. DOI: 10.2147/DDDT.S221437. View

20.

Daumann J, Heekeren K, Neukirch A, Thiel C, Moller-Hartmann W, Gouzoulis-Mayfrank E . Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl). 2008; 200(4):573-83. DOI: 10.1007/s00213-008-1237-1. View